Literature DB >> 15603562

Threshold values of maternal blood glucose in early diabetic pregnancy--prediction of fetal malformations.

E Wender-Ozegowska1, K Wróblewska, A Zawiejska, M Pietryga, J Szczapa, R Biczysko.   

Abstract

BACKGROUND: The prevention of congenital malformations in the newborns of diabetic mothers still constitutes one of the main problems in this group of patients. AIM: The aim of this study was to analyze the prevalence of fetal malformations in diabetic pregnancies, as well as detection of the cut-off points for the first-trimester glycemia levels, relating to diabetes-induced fetal malformations.
METHODS: The data for analysis were collected retrospectively from the case histories of diabetic pregnant women and their newborns, treated in our departments. For the evaluation of maternal diabetes control, the whole-day glycemia profiles as well as glycated hemoglobin (HbA1C) levels were registered. To establish the glucose cut-off values for malformations, we have used receiver operating characteristic (ROC) curves for fasting, 1-hr, and 2-hr postprandial glucose levels. To determine how metabolic control influences the risk of giving birth to a malformed infant, we followed 198 newborns of diabetic mothers and 4700 infants born of healthy mothers (control group).
RESULTS: We detected malformations in the infants of 8.6% (n = 17) of diabetic mothers and 3.8% of the control (odds ratio: 2.35, 95% CI = 1.40-3.96). We compared this group of diabetic patients to another diabetic pregnancy group, analyzed over a period of 1988-93 (n = 209), in which 13 newborns (6.2%) manifested congenital malformations (odds ratio: 1.41, 95% CI = 0.67-2.99) (the difference was statistically insignificant). HbA1C level during organogenesis was not significantly higher in women whose infants were malformed. We proved, however, that the risk of malformations was higher, when HbA1C value exceeded 9.3%. The malformation rate in diabetes classes D-H (according to White) was higher than in classes B and C, but the difference was not significant. A wide spectrum of anomalies has been observed in the newborns of diabetic mothers.
CONCLUSIONS: Our results confirm the view that diabetic pregnancy, despite the improved metabolic control, is still a strong risk factor for alterations in fetal development, particularly in patients with a tendency to brittle glycemia during first trimester of pregnancy. It seems that keeping fasting glucose levels in first trimester below 5.8 mmol/l and postprandial glucose levels below 9.1 mmol/l can contribute to decreasing number of fetal malformations in pregestational diabetes mellitus (PGDM) pregnancy. The ROC curves appear to be useful and adequate tool for the analysis of factors influencing fetal development in diabetic pregnancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15603562     DOI: 10.1111/j.0001-6349.2005.00606.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  11 in total

1.  Expression of apoptosis-regulatory genes in the hippocampus of rat neonates born to mothers with diabetes.

Authors:  Hossein Haghir; Javad Hami; Nassim Lotfi; Mostafa Peyvandi; Simagol Ghasemi; Mehran Hosseini
Journal:  Metab Brain Dis       Date:  2017-01-11       Impact factor: 3.584

Review 2.  Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis.

Authors:  Rinat Gabbay-Benziv; E Albert Reece; Fang Wang; Peixin Yang
Journal:  World J Diabetes       Date:  2015-04-15

3.  Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design.

Authors:  Raksha Jain; Amalia Magaret; Phuong T Vu; Jill M VanDalfsen; Ashley Keller; Alexandra Wilson; Melissa S Putman; Nicole Mayer-Hamblett; Charles R Esther; Jennifer L Taylor-Cousar
Journal:  BMJ Open Respir Res       Date:  2022-06

4.  Disorders in glucidic metabolism and congenital heart diseases: detection and prevention.

Authors:  G Passarella; G Trifirò; M Gasparetto; G Svaluto Moreolo; O Milanesi
Journal:  Pediatr Cardiol       Date:  2012-11-15       Impact factor: 1.655

5.  Prenatal diagnosis of caudal regression syndrome without maternal diabetes mellitus.

Authors:  Ahmet Özgür Yeniel; Ahmet Mete Ergenoğlu; Sermet Sağol
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-09-01

6.  Descriptive and risk factor analysis of nonsyndromic sacral agenesis: National Birth Defects Prevention Study, 1997-2011.

Authors:  Marine Nalbandyan; Meredith M Howley; Christopher M Cunniff; Paul A Romitti; Marilyn L Browne
Journal:  Am J Med Genet A       Date:  2019-07-11       Impact factor: 2.802

7.  Exome sequencing identifies variants in infants with sacral agenesis.

Authors:  Georgia Pitsava; Marcia L Feldkamp; Nathan Pankratz; John Lane; Denise M Kay; Kristin M Conway; Charlotte Hobbs; Gary M Shaw; Jennita Reefhuis; Mary M Jenkins; Lynn M Almli; Cynthia Moore; Martha Werler; Marilyn L Browne; Chris Cunniff; Andrew F Olshan; Faith Pangilinan; Lawrence C Brody; Robert J Sicko; Richard H Finnell; Michael J Bamshad; Daniel McGoldrick; Deborah A Nickerson; James C Mullikin; Paul A Romitti; James L Mills
Journal:  Birth Defects Res       Date:  2022-03-10       Impact factor: 2.661

8.  Scoliotic deformity and asymptomatic cervical syrinx in a 9 year old with caudal regression syndrome.

Authors:  Ankur Singh; Seema Kapoor; Gaurav Pradhan; V K Gautam; Simmi K Ratan
Journal:  J Pediatr Neurosci       Date:  2012-09

9.  Adverse pregnancy outcomes in women with diabetes.

Authors:  Carlos Antonio Negrato; Rosiane Mattar; Marilia B Gomes
Journal:  Diabetol Metab Syndr       Date:  2012-09-11       Impact factor: 3.320

10.  Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies.

Authors:  Melanie E Inkster; Tom P Fahey; Peter T Donnan; Graham P Leese; Gary J Mires; Deirdre J Murphy
Journal:  BMC Pregnancy Childbirth       Date:  2006-10-30       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.